Literature DB >> 2423656

Calmodulin: a potential target for cancer chemotherapeutic agents.

W N Hait, J S Lazo.   

Abstract

Calmodulin is a ubiquitous, calcium-binding protein that is responsible for many of the intracellular actions of calcium. Recent evidence suggests that calmodulin may regulate cellular proliferation and that its function may be altered in malignancy. The discovery that drugs such as phenothiazines antagonize the action of calmodulin led to the study of these antagonists against tumor cells. It is now appreciated that calmodulin antagonists are cytotoxic, can restore the sensitivity of resistant cells to drugs such as doxorubicin and vincristine, and can augment the cytotoxicity of bleomycin. This report addresses the possibility of developing new forms of chemotherapeutic agents that work by disrupting the function of this intriguing molecule.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423656     DOI: 10.1200/JCO.1986.4.6.994

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Functional dynamics of the hydrophobic cleft in the N-domain of calmodulin.

Authors:  D Vigil; S C Gallagher; J Trewhella; A E García
Journal:  Biophys J       Date:  2001-05       Impact factor: 4.033

2.  Trifluoperazine regulation of calmodulin binding to Fas: a computational study.

Authors:  Di Pan; Qi Yan; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Proteins       Date:  2011-06-07

3.  Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1.

Authors:  Yong P Hwang; Hye G Jeong
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.

Authors:  Ching-Hsien Chen; Sarah Statt; Chun-Lung Chiu; Philip Thai; Muhammad Arif; Kenneth B Adler; Reen Wu
Journal:  Am J Respir Crit Care Med       Date:  2014-11-15       Impact factor: 21.405

5.  Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.

Authors:  Romone M Fancy; Harrison Kim; Tong Zhou; Kurt R Zinn; Donald J Buchsbaum; Yuhua Song
Journal:  J Cell Biochem       Date:  2017-04-12       Impact factor: 4.429

6.  Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine.

Authors:  W N Hait; S Morris; J S Lazo; R J Figlin; H J Durivage; K White; P E Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Evidence for a calmodulin inhibitory substance(s) isolated from human meningiomas.

Authors:  S D Antle; A K Ho; U P Kalyan-Raman
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

8.  A murine model for bone marrow metastasis established by an i.v. injection of C-1300 neuroblastoma in A/J mice.

Authors:  M Iwakawa; K Ando; H Ohkawa; S Koike; Y J Chen
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

9.  Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.

Authors:  Yan-lin Wei; Lei Xu; Yun Liang; Xiao-hua Xu; Xiao-ying Zhao
Journal:  Acta Pharmacol Sin       Date:  2009-03-09       Impact factor: 6.150

10.  The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells.

Authors:  Eun-Young Ahn; George Pan; Jae Hwan Oh; Ewan M Tytler; Jay M McDonald
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.